A CD79b targeting ADC with superior anti-tumor activity and therapeutic index

被引：0

作者：

Attinger-Toller, Isabella ^{[1
]}

Probst, Philipp ^{[1
]}

Bertrand, Romain ^{[1
]}

Stark, Ramona ^{[1
]}

Santimaria, Roger ^{[1
]}

Renard, Emma ^{[1
]}

Fay, Rachael ^{[1
]}

Grabulovski, Dragan ^{[1
]}

Schlereth, Bernd ^{[1
]}

Spycher, Philipp Rene ^{[1
]}

机构：

[1] Araris Biotech AG, Zurich, Switzerland

来源：

CANCER RESEARCH | 2022年 / 82卷 / 12期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2910

引用

页数：1

共 50 条

[11] Blocking CD47 Shows Superior Anti-tumor Therapeutic Effects of Bevacizumab in Gastric Cancer [J].

Shi, Chenyang ;

Li, Jiaxin ;

Fan, Guorong ;

Liu, Yu .

FRONTIERS IN PHARMACOLOGY, 2022, 13

[12] United we stand: Double targeting of CD79B and CD20 in diffuse large B-cell lymphoma [J].

Tarantelli, Chiara ;

Bertoni, Francesco .

BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (02) :169-170

[13] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [J].

Ding, Shengnan ;

Mao, Xia ;

Cao, Yang ;

Wang, Na ;

Xu, Hao ;

Zhou, Jianfeng .

TARGETED ONCOLOGY, 2020, 15 (03) :365-375

[14] Targeting CD79b for Chimeric Antigen Receptor T-Cell Therapy of B-Cell Lymphomas [J].

Shengnan Ding ;

Xia Mao ;

Yang Cao ;

Na Wang ;

Hao Xu ;

Jianfeng Zhou .

Targeted Oncology, 2020, 15 :365-375

[15] A bispecific HER2 targeting FynomAb with superior anti-tumor activity and novel mode of action [J].

Schade, Babette ;

Brack, Simon ;

Attinger-Toller, Isabella ;

Klupsch, Kristina ;

Woods, Richard ;

Hachemi, Helen ;

von der Bey, Ulrike ;

Kooenig-Friedrich, Susann ;

Bertschinger, Julian ;

Grabulovski, Dragan .

CANCER RESEARCH, 2014, 74 (19)

[16] IMMUNOMODULATORY EFFECTS OF MGD010, A DART® MOLECULE TARGETING HUMAN B-CELL CD32B AND CD79B [J].

Chen, W. ;

Shankar, S. ;

Lohr, J. ;

Yao, X. -T. ;

Li, H. ;

Chen, X. ;

Muth, J. ;

Gal-Edd, N. ;

Bonvini, E. ;

Johnson, S. ;

Pandya, N. ;

Moore, P. A. ;

Wigginton, J. .

ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 :777-778

[17] CD62L+NKT cells have superior in vivo persistence and anti-tumor activity [J].

Tian, Gengwen ;

Courtney, Amy N. ;

Jena, Bipulendu ;

Heczey, Andras ;

Liu, Daofeng ;

Marinova, Ekaterina ;

Guo, Linjie ;

Xu, Xin ;

Dotti, Gianpietro ;

Cooper, Laurence J. ;

Metelitsa, Leonid S. .

JOURNAL OF IMMUNOLOGY, 2016, 196

[18] NSD proteins in anti-tumor immunity and their therapeutic targeting by protein degraders [J].

Chava, Suresh ;

Wajapeyee, Narendra .

CELLULAR AND MOLECULAR LIFE SCIENCES, 2025, 82 (01)

[19] A tumor microenvironment-targeting CD98-directed ADC confers robust anti-tumor activity in multiple cancers with favorable pharmacokinetics and safety profiles in preclinical models [J].

Yang, Fang ;

Wang, Lei ;

Tian, Xinxin ;

Qiu, Xuan ;

Chen, Jianhe ;

Qi, Wenke ;

Li, Guangyu ;

Liu, Haidong ;

Liu, Juan ;

Huang, Suping ;

Ye, Bin ;

Wu, Qilin ;

Zhao, Baiteng ;

Li, Wenhui ;

Sui, Jianhua ;

Chen, Zhu .

CANCER RESEARCH, 2024, 84 (07)

[20] B-cell inhibition by cross-linking CD79b is superior to B-cell depletion with anti-CD20 antibodies in treating murine collagen-induced arthritis [J].

Bruehl, Hilke ;

Cihak, Josef ;

Talke, Yvonne ;

Gomez, Manuel Rodriguez ;

Hermann, Fabian ;

Goebel, Nicole ;

Renner, Kerstin ;

Plachy, Jiri ;

Stangassinger, Manfred ;

Aschermann, Susanne ;

Nimmerjahn, Falk ;

Mack, Matthias .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2015, 45 (03) :705-715

← 1 2 3 4 5 →